Key takeaways for Maryland
- • No GLP-1 is FDA-approved for PCOS — entirely off-label.
- • BMI 27+ may qualify under standard Wegovy/Zepbound labels if comorbidities present.
- • Improvements seen in insulin resistance, weight, and androgens; fertility data limited.
- • Maryland Medicaid (HealthChoice) coverage rules apply for PCOS (Polycystic Ovary Syndrome) patients in Maryland — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for PCOS (Polycystic Ovary Syndrome)
No GLP-1 is FDA-approved specifically for PCOS. However, small randomized trials and observational studies show GLP-1 RAs improve insulin sensitivity, support 5-15% weight loss, reduce free testosterone, and may improve menstrual regularity and ovulation. Evidence grade: C-B (smaller trials, growing evidence base). PCOS guidelines (ESHRE/Monash 2023) recognize obesity-targeted pharmacotherapy as adjunct. Patients trying to conceive should stop GLP-1s at least 2 months before pregnancy attempts.
Maryland-specific context
Maryland has telehealth access concentrated in Baltimore, Frederick, Rockville metros, with additional reach to Gaithersburg and Bowie. Johns Hopkins Medicine, University of Maryland Medical System is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.maryland.gov.
Marylandtelehealth & pricing rules
- • Maryland requires a live video consultation before a GLP-1 prescription.
- • Maryland allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Maryland: ~$318/mo (compounded options often lower, brand higher).